Answers are grounded in this paper and cite their sources.
Background Despite substantial improvements in survival, relapse and treatment resistance remain important challenges in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Ferroptosis, an iron-dependent form of regulated cell death characterized by phospholipid peroxidation, has emerged as a potential therapeutic vulnerability in leukemia. However, the extent to which ferroptosis contributes to treatment resistance in pediatric B-ALL remains uncertain. Methods A narrative literature search was conducted in PubMed/MEDLINE, Embase, and Scopus for English-language publications available through August 2, 2026. Studies addressing iron homeostasis, ferroptosis, treatment resistance, and CAR-T-cell therapy were considered. Evidence was classified according to study population and experimental setting and synthesized narratively, with emphasis on distinguishing pediatric clinical findings from experimental and indirect evidence. Main findings This narrative review examines the relationship between iron homeostasis, ferroptosis-regulating pathways, treatment resistance, and CAR-T-cell function, with particular emphasis on pediatric B-ALL. Available studies suggest that iron availability, ferritin-mediated iron storage, and antioxidant pathways may influence leukemia-cell susceptibility to ferroptosis. Evidence from CAR-T-cell studies involving B-cell and plasma-cell malignancies, together with experimental solid-tumor models, indicates that ferroptosis-related pathways may influence both therapeutic T-cell function and malignant-cell susceptibility to immune-mediated killing. These findings arise from heterogeneous clinical-sample analyses and preclinical investigations, with limited direct validation in pediatric B-ALL. Conclusion The iron–ferroptosis axis represents a promising but incompletely validated therapeutic target in pediatric B-ALL. Although experimental findings support its potential relevance to leukemia-cell survival and CAR-T-cell function, direct pediatric clinical evidence remains limited. Further studies using pediatric patient-derived models and clinical samples are needed.
No takes yet. Share an insight, caveat, or question.
Bitar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: